A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Orteronel (Primary) ; Bicalutamide; Leuprorelin; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms SWOG 1216
- 29 Aug 2024 Results of subset analysis published in the Prostate Cancer and Prostatic Diseases.
- 04 Jun 2024 Results of Patient level data from this study analyzing Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC), presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 27 Jan 2024 Results of Patient level data from this study analyzing Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer, presented at the 2024 Genitourinary Cancers Symposium